Publication: 4608

Publication: 4608

Alliance A092104 - A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy

DOI

Google Scholar

Citation:

Meeting Instance:: ASCO 2025
Year:: 2025
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Experimental
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882; U24CA19617; U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG Oncology);

Corr. Author:
Authors:: Brian A. Van Tine Jake Allred Martee L. Hensley Rebecca C. Arend John Charlson Gina D'Amato Thersa Lee Elizabeth Loggers Stephane Berg Matthew Ingham Sumithra J. Mandrekar Gary K Schwartz

Networks:: COLUMBIA, FL028, LAPS-MN026, LAPS-MO011, LAPS-NY016, OH029

Study: Alliance-A092104
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2/3

Keywords: